Bracco Diagnostics Inc

FDA Expands Max 3™ Syringeless MRI Injector for Use with VUEWAY® Imaging Bulk Package

- The FDA has expanded the indication for Bracco's Max 3™ syringeless MRI injector to include use with VUEWAY® (gadopiclenol) injection Imaging Bulk Package in 30 mL and 50 mL formats. - The Max 3™ is the first and only syringeless MRI injector available in the U.S. market, designed for precise, efficient, and hygienic contrast delivery. - VUEWAY® provides effective contrast enhancement at half the gadolinium dose compared to other macrocyclic GBCAs, with over three million injections administered at more than 902 customer sites. - The multi-dose IBP packaging enables delivery of multiple single doses from one container, reducing material waste and improving workflow efficiency.